Mitomycin C, widely used to prevent scarring after glaucoma surgery, triggers a senescence-associated secretory phenotype in surviving fibroblasts that perpetuates inflammation and fibrosis. Senolytic agents can selectively eliminate these cells, offering a complementary strategy to improve surgical durability.
Key Points
- Mitomycin C induces SASP-like senescence in postoperative fibroblasts
- Senescent fibroblasts drive inflammation via CCL7 and other cytokines
- Senolytics selectively remove these cells, improving surgical outcomes
Longevity Analysis
Surgical interventions often create unintended cellular consequences—in this case, chemically induced senescence that generates persistent inflammatory signaling long after the initial wound-healing phase. The fibroblasts survive the antimetabolite treatment but enter a dysfunctional state, continuously secreting factors that promote fibrosis and tissue remodeling. This reveals why standard surgical approaches plateau in efficacy: the drug solves one problem (excessive scarring) by eliminating proliferating cells, but leaves behind a population of senescent cells that leak inflammatory mediators. Targeting these senescent cells directly—rather than relying solely on the initial drug effect—addresses the root driver of late-stage surgical failure. This principle extends beyond ophthalmology: any intervention that uses senescence-inducing agents as a feature rather than a bug may benefit from follow-up senolytic treatment to clear the residual inflammatory burden.
Original published by Wiley Aging Cell, by Akitoshi Kimura, Tomokazu Fujimoto, Satoshi Iraha, Kei‐Ichiro Yasunaga, Miyuki Inoue‐Mochita, Naofumi Funagura, Shunsuke Tanigawa, Daisuke Kurotaki, Tomoaki Koga, Fumika Watanabe‐Kitamura, Utako Tsutsumi‐Kuroda, Mitsuyoshi Nakao, Toshihiro Inoue .